Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -42.98% is 56% below its 2-year average of -27.58%, near the low end of its 2-year range (-42.98%–-13.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.58% below its 12-month average of -35.65%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -42.98%.
RETURN ON INVESTED CAPITAL (ROIC)
-42.98%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-35.65%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-20.58%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-25.42%
median of 377 covered companies
CURRENT VS SECTOR MEDIAN
-69.09%
vs the sector median at left
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
Return on Invested Capital (ROIC)
-42.98%
TTM Avg
-35.65%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
Return on Invested Capital (ROIC)
-6.33%
TTM Avg
-3.44%
3Y Avg
-10.34%
5Y Avg
-8.68%
Market Cap
$1.12B
Return on Invested Capital (ROIC)
5.93%
TTM Avg
9.95%
3Y Avg
11.37%
5Y Avg
9.31%
Market Cap
$1.16B
Return on Invested Capital (ROIC)
3.72%
TTM Avg
3.50%
3Y Avg
1.32%
5Y Avg
-2.22%
Market Cap
$1.20B
Return on Invested Capital (ROIC)
-67.73%
TTM Avg
-67.73%
3Y Avg
-67.73%
5Y Avg
-67.73%
Market Cap
$1.21B
Return on Invested Capital (ROIC)
1.12%
TTM Avg
-4.20%
3Y Avg
-6.46%
5Y Avg
-10.06%
Market Cap
$1.05B
Return on Invested Capital (ROIC)
-7.32%
TTM Avg
-21.18%
3Y Avg
-91.27%
5Y Avg
-61.58%
Market Cap
$1.24B
Return on Invested Capital (ROIC)
-52.44%
TTM Avg
-96.82%
3Y Avg
-100.85%
5Y Avg
-77.97%
Market Cap
$989.05M
Return on Invested Capital (ROIC)
-16.54%
TTM Avg
-24.45%
3Y Avg
-23.43%
5Y Avg
-23.43%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | -42.98% | -35.65% | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | -6.33% | -3.44% | -10.34% | -8.68% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 5.93% | 9.95% | 11.37% | 9.31% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 3.72% | 3.50% | 1.32% | -2.22% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | -67.73% | -67.73% | -67.73% | -67.73% |
| Cronos Group Inc. (CRON)vs › | $1.21B | 1.12% | -4.20% | -6.46% | -10.06% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -7.32% | -21.18% | -91.27% | -61.58% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | -52.44% | -96.82% | -100.85% | -77.97% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | -16.54% | -24.45% | -23.43% | -23.43% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | -68.64% | -46.08% | -28.67% | -26.80% |
ROIC
-43.0%
ROE
-39.5%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -42.98% |
| 2026-03-31 | -33.85% |
| 2025-12-31 | -38.70% |
| 2025-09-30 | -34.96% |
| 2025-06-30 | -27.75% |
| 2025-03-31 | -23.71% |
| 2024-12-31 | -14.93% |
| 2024-09-30 | -13.62% |
| 2024-06-30 | -30.27% |
| 2024-03-31 | -24.35% |
| 2023-12-31 | -18.22% |
